Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p52
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 52/191)
Character Range: 10069577–10085548

treatment
                                                                                                                                                                                                                               The condition must be characterised by the presence of the t(15:
                                                                                                                                                                                                                                17) translocation or PML/RAR-alpha fusion gene transcript.
C6023               P6023          CN6023           Fluconazole                                                                                                                                                                Oropharyngeal candidiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 6023
                                                                                                                                                                                                                               Patient must be immunosuppressed.
C6026               P6026          CN6026           Fentanyl                                                                                                                                                                   Breakthrough pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures
                                                                                                                                                                                                                               Initial treatment for dose titration
                                                                                                                                                                                                                               Patient must have cancer; AND
                                                                                                                                                                                                                               Patient must have pain directly attributable to cancer; AND
                                                                                                                                                                                                                               Patient must be assessed as receiving adequate management of their persistent pain with opioids; AND
                                                                                                                                                                                                                               Patient must have previously experienced inadequate pain relief following adequate doses of short acting opioids for the treatment of breakthrough pain; or
                                                                                                                                                                                                                               The treatment must be used as short acting opioids are considered clinically inappropriate; or
                                                                                                                                                                                                                               Patient must have previously experienced adverse effects following the use of short acting opioids for breakthrough pain; AND
                                                                                                                                                                                                                               Patient must be undergoing palliative care.
C6027               P6027          CN6027           Fentanyl                                                                                                                                                                   Breakthrough pain                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Compliance with Authority Required procedures
                                                                                                                                                                                                                               Continuing treatment
                                                                                                                                                                                                                               Patient must have cancer; AND
                                                                                                                                                                                                                               Patient must have pain directly attributable to cancer; AND
                                                                                                                                                                                                                               Patient must be assessed as receiving adequate management of their persistent pain with opioids; AND
                                                                                                                                                                                                                               Patient must have previously experienced inadequate pain relief following adequate doses of short acting opioids for the treatment of breakthrough pain; or
                                                                                                                                                                                                                               The treatment must be used as short acting opioids are considered clinically inappropriate; or
                                                                                                                                                                                                                               Patient must have previously experienced adverse effects following the use of short acting opioids for breakthrough pain; AND
                                                                                                                                                                                                                               Patient must be undergoing palliative care.
C6030               P6030          CN6030           Fluconazole                                                                                                                                                                Oropharyngeal candidiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 6030
                                                                                                                                                                                                                               The treatment must be for prophylaxis; AND
                                                                                                                                                                                                                               Patient must be immunosuppressed.
C6031               P6031          CN6031           Fluconazole                                                                                                                                                                Oropharyngeal candidiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 6031
                                                                                                                                                                                                                               Patient must be immunosuppressed; AND
                                                                                                                                                                                                                               Patient must be unable to take a solid dose form of fluconazole.
C6032               P6032          CN6032           Fluconazole                                                                                                                                                                Oropharyngeal candidiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Compliance with Authority Required procedures - Streamlined Authority Code 6032
                                                                                                                                                                                                                               The treatment must be for prophylaxis; AND
                                                                                                                                                                                                                               Patient must be immunosuppressed; AND
                                                                                                                                                                                                                               Patient must be unable to take a solid dose form of fluconazole.
C6036               P6036          CN6036           Artemether with lumefantrine                                                                                                                                               Confirmed or suspected Plasmodium falciparum malaria
                                                                                                                                                                                                                               Patient must be unable to swallow a solid dosage form of artemether with lumefantrine.
C6038               P6038          CN6038           Amino acid formula with vitamins and minerals without methionine                                                                                                           Pyridoxine non-responsive homocystinuria

C6046               P6046          CN6046           Fluconazole                                                                                                                                                                Oesophageal candidiasis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Compliance with Authority Required procedures - Streamlined Authority Code 6046
                                                                                                                                                                                                                               Patient must be immunosuppressed; AND
                                                                                                                                                                                                                               Patient must be unable to take a solid dose form of fluconazole.
C6055               P6055          CN6055           Amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine                                                               Methylmalonic acidaemia

C6056               P6056          CN6056           Carmustine                                                                                                                                                                 Glioblastoma multiforme
                                                                                                                                                                                                                               The condition must